BioSpace News Archive

Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the second quarter ended June 30, 2023.

Anavex Life Sciences Corp. today reported financial results for its fiscal quarter ended June 30, 2023.

Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced financial results for the second quarter ended June 30, 2023.

CorMedix Inc. today announced financial results for the second quarter and six months ended June 30, 2023 and provided an update on recent business events.

Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or “the Company”), a global leader in innovations for active healing, today reported financial results for the three and six months ended July 1, 2023.

Organon (NYSE: OGN) today announced its results for the second quarter ended June 30, 2023.

Aspen Neuroscience today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application, enabling the company to proceed with a clinical trial for ANPD001.

Sparian Biosciences, Inc., a clinical-stage CNS-focused biopharmaceutical company, announced that it has been awarded a $19 million, five-year grant to fund development of SBS-518 from IND submission through Phase 1 clinical development.

SYSNAV Healthcare announces that the European Medicines Agency considers that for ambulant Duchenne Muscular Dystrophy patients four years of age and above, Stride Velocity 95th centile qualifies as primary endpoint in superiority studies as an alternative to the 6 Minute Walking Test provided this outcome measure is supported by consistent findings in established efficacy endpoints included in secondary endpoints.

Harbour BioMed, a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immunology announced the appointment of Dr. Albert R. Collinson as independent non-executive director.